Literature DB >> 7745412

Noradrenaline concentrations and electrocardiographic abnormalities after aneurysmal subarachnoid haemorrhage.

P J Brouwers1, H G Westenberg, J Van Gijn.   

Abstract

Serial ECGs and serial assessment of plasma noradrenaline concentrations were carried out in 37 consecutive patients with aneurysmal subarachnoid haemorrhage and 18 operated controls. Electrocardiographic abnormalities reflecting possible signs of cardiac ischaemia occurred significantly more often in patients than in controls. By contrast, plasma noradrenaline concentrations were much higher in controls than in patients. Plasma noradrenaline concentrations were higher in patients with poor outcome, particularly after the third day, but showed covariance with established predictors of outcome such as the Glasgow coma scale score on admission, the amount of extravasated blood on the initial CT, and age. In conclusion, high plasma noradrenaline concentrations do not explain the occurrence of electrocardiographic abnormalities, and are not useful as independent predictors of poor outcome or secondary complications.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7745412      PMCID: PMC1073495          DOI: 10.1136/jnnp.58.5.614

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  18 in total

1.  Effect of elevated plasma norepinephrine on electrocardiographic changes in subarachnoid hemorrhage.

Authors:  A Grad; T Kiauta; J Osredkar
Journal:  Stroke       Date:  1991-06       Impact factor: 7.914

2.  Levels of catecholamine in plasma and cerebrospinal fluid in aneurysmal subarachnoid hemorrhage.

Authors:  A Dilraj; J H Botha; V Rambiritch; R Miller; J R van Dellen
Journal:  Neurosurgery       Date:  1992-07       Impact factor: 4.654

3.  Hypothalamic and myocardial lesions after subarachnoid haemorrhage.

Authors:  R Doshi; G Neil-Dwyer
Journal:  J Neurol Neurosurg Psychiatry       Date:  1977-08       Impact factor: 10.154

4.  Serial electrocardiographic recording in aneurysmal subarachnoid hemorrhage.

Authors:  P J Brouwers; E F Wijdicks; D Hasan; M Vermeulen; E F Wever; H Frericks; J van Gijn
Journal:  Stroke       Date:  1989-09       Impact factor: 7.914

5.  Assessment of coma and impaired consciousness. A practical scale.

Authors:  G Teasdale; B Jennett
Journal:  Lancet       Date:  1974-07-13       Impact factor: 79.321

6.  Approaches to sudden death from coronary heart disease.

Authors:  B Lown; M Wolf
Journal:  Circulation       Date:  1971-07       Impact factor: 29.690

7.  Separation of tissue and serum creatine kinase isoenzymes by ion-exchange column chromatography.

Authors:  D W Mercer
Journal:  Clin Chem       Date:  1974       Impact factor: 8.327

8.  Assessment of outcome after severe brain damage.

Authors:  B Jennett; M Bond
Journal:  Lancet       Date:  1975-03-01       Impact factor: 79.321

9.  Prediction of delayed cerebral ischemia, rebleeding, and outcome after aneurysmal subarachnoid hemorrhage.

Authors:  A Hijdra; J van Gijn; N J Nagelkerke; M Vermeulen; H van Crevel
Journal:  Stroke       Date:  1988-10       Impact factor: 7.914

10.  Effect of propranolol and phentolamine on myocardial necrosis after subarachnoid haemorrhage.

Authors:  G Neil-Dwyer; P Walter; J M Cruickshank; B Doshi; P O'Gorman
Journal:  Br Med J       Date:  1978-10-07
View more
  9 in total

Review 1.  Extracerebral organ dysfunction in the acute stage after aneurysmal subarachnoid hemorrhage.

Authors:  Wouter J Schuiling; Paul J W Dennesen; Gabriël J E Rinkel
Journal:  Neurocrit Care       Date:  2005       Impact factor: 3.210

2.  Predictors of left ventricular regional wall motion abnormalities after subarachnoid hemorrhage.

Authors:  Avinash Kothavale; Nader M Banki; Alexander Kopelnik; Sirisha Yarlagadda; Michael T Lawton; Nerissa Ko; Wade S Smith; Barbara Drew; Elyse Foster; Jonathan G Zaroff
Journal:  Neurocrit Care       Date:  2006       Impact factor: 3.210

Review 3.  How to increase the utilization of donor hearts?

Authors:  Maya Guglin
Journal:  Heart Fail Rev       Date:  2015-01       Impact factor: 4.214

4.  Prevalence and implications of diastolic dysfunction after subarachnoid hemorrhage.

Authors:  Alexander Kopelnik; Landis Fisher; Jacob C Miss; Nader Banki; Poyee Tung; Michael T Lawton; Nerissa Ko; Wade S Smith; Barbara Drew; Elyse Foster; Jonathan Zaroff
Journal:  Neurocrit Care       Date:  2005       Impact factor: 3.210

5.  Cardiac abnormalities after aneurysmal subarachnoid hemorrhage: effects of β-blockers and angiotensin-converting enzyme inhibitors.

Authors:  Elizabeth Crago; Kelly Kerris; Chien-Wen J Kuo; Paula Sherwood; Marilyn Hravnak; David Crippen; Michael Horowitz
Journal:  Am J Crit Care       Date:  2014-01       Impact factor: 2.228

6.  Association between elevated plasma norepinephrine levels and cardiac wall motion abnormality in poor-grade subarachnoid hemorrhage patients.

Authors:  Keiko Sugimoto; Joji Inamasu; Yoko Kato; Yasuhiro Yamada; Tsukasa Ganaha; Motoki Oheda; Natsuki Hattori; Eiichi Watanabe; Yukio Ozaki; Yuichi Hirose
Journal:  Neurosurg Rev       Date:  2012-08-31       Impact factor: 3.042

7.  Cardiac wall motion abnormality after bleeding from vertebral artery aneurysms.

Authors:  Joji Inamasu; Takuro Hayashi; Motoki Oheda; Kei Yamashiro; Shinichiro Tateyama; Hirotaka Kogame; Yasuhiro Yamada; Keiko Sugimoto; Eiichi Watanabe; Yoko Kato; Yuichi Hirose
Journal:  Clin Auton Res       Date:  2014-10-02       Impact factor: 4.435

8.  Prolonged elevated heart rate is a risk factor for adverse cardiac events and poor outcome after subarachnoid hemorrhage.

Authors:  J Michael Schmidt; Michael Crimmins; Hector Lantigua; Andres Fernandez; Chris Zammit; Cristina Falo; Sachin Agarwal; Jan Claassen; Stephan A Mayer
Journal:  Neurocrit Care       Date:  2014-06       Impact factor: 3.210

Review 9.  The harmful effects of subarachnoid hemorrhage on extracerebral organs.

Authors:  Sheng Chen; Qian Li; Haijian Wu; Paul R Krafft; Zhen Wang; John H Zhang
Journal:  Biomed Res Int       Date:  2014-07-07       Impact factor: 3.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.